CROSSJECT, a specialty pharmaceutical company focused on emergency treatments using its needle-free ZENEO® auto-injector technology, announced that Portzamparc (BNP Paribas Group) has initiated coverage of its stock. The research report, titled “The needles will soon be nothing more than a bad memory,” includes a “Strong Buy” recommendation and sets a target price of €4.50 per share.
CROSSJECT is currently advancing the development and regulatory approval of ZEPIZURE®, an injectable treatment for epileptic seizures, supported by a $60 million contract with BARDA. The company’s ZENEO® platform allows for easy intramuscular drug delivery without needles, even through clothing, and is being developed for other emergency conditions such as allergic shocks and adrenal insufficiencies.
**Why this matters**
The initiation of coverage by a major financial institution like Portzamparc highlights growing investor interest in CROSSJECT’s innovative drug delivery technology and its pipeline. The “Strong Buy” rating and target price suggest positive market expectations for the company’s upcoming product launches and potential growth in the emergency pharmaceutical sector.
Source: NewsData